Skye Bioscience IncOTCQB:SKYE
- LAST PRICE0.0223
- TODAY'S CHANGE (%)-0.0007 (-3.2609%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0220 / 0.0230
- Day Range
- 52 Week Range
- Volume345,938
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SKYE |
|---|---|---|
| 09:32 ET | 73487 | 0.023 |
| 09:59 ET | 1300 | 0.0225 |
| 10:06 ET | 1000 | 0.023 |
| 10:17 ET | 1560 | 0.022 |
| 10:30 ET | 390 | 0.022 |
| 10:46 ET | 21000 | 0.022 |
| 10:55 ET | 1302 | 0.022 |
| 10:57 ET | 8450 | 0.023 |
| 11:04 ET | 18649 | 0.023 |
| 11:15 ET | 10000 | 0.023 |
| 12:00 ET | 100 | 0.022 |
| 12:02 ET | 195 | 0.022 |
| 12:05 ET | 1100 | 0.0229 |
| 12:12 ET | 1950 | 0.02245 |
| 12:56 ET | 83000 | 0.02245 |
| 01:12 ET | 2227 | 0.02225 |
| 01:26 ET | 20000 | 0.022 |
| 01:46 ET | 3500 | 0.02225 |
| 01:51 ET | 1600 | 0.02225 |
| 02:22 ET | 10000 | 0.02225 |
| 02:24 ET | 14328 | 0.02225 |
| 02:36 ET | 1000 | 0.02225 |
| 02:49 ET | 1000 | 0.0225 |
| 03:03 ET | 118 | 0.02225 |
| 03:27 ET | 577 | 0.0222 |
| 03:38 ET | 62600 | 0.02225 |
| 03:54 ET | 5000 | 0.02225 |
Mar 15, 2023
Mar 7, 2023
Skye Bioscience Doses Third Cohort of Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion, from 7:01AM ET on Tuesday Mar 07, 2023 by Newsfile
7:01AM ET on Tuesday Mar 07, 2023 by Newsfile
Feb 23, 2023
Skye Bioscience Receives Positive Safety Review of SBI-100 Ophthalmic Emulsion After Second Cohort of Phase 1 Study, from 7:01AM ET on Thursday Feb 23, 2023 by Newsfile
7:01AM ET on Thursday Feb 23, 2023 by Newsfile
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Skye Bioscience Inc | 21.4M | -0.9x | --- |
Oncotelic Therapeutics Inc | 21.5M | 3.0x | --- |
Better Therapeutics Inc | 21.6M | -0.3x | --- |
Edesa Biotech Inc | 20.9M | -1.0x | --- |
AIM ImmunoTech Inc | 21.2M | -1.0x | --- |
Forte Biosciences Inc | 20.6M | -1.2x | --- |
Company Information
Skye Bioscience Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of a class of cannabinoid derivatives to modulate the endocannabinoid system. The Company is also focused on developing cannabinoid derivatives that have the potential to treat ophthalmic disorders and other diseases with unmet needs. Its lead product candidate, SBI-100, is being developed for the treatment of glaucoma and ocular hypertension. SBI-100 is designed to make the usually lipophilic cannabinoid more hydrophilic to allow for improved transport across the membranes of the eye. It is also focused on developing different formulations of SBI-200. Early studies of SBI-200 demonstrated analgesic, anti- inflammatory, anti-fibrotic and anti-seizure properties, including the potential treatment and management of several eye diseases, such as uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy.
Contact Information
- Headquarters
- 11250 EL CAMINO REAL, SUITE 100SAN DIEGO, CA, United States 92130
- Phone
- 858-410-0266
- Fax
- 775-782-2611
Executives
- Chairman of the Board, President, Company Secretary
- Punit Dhillon
- Chief Financial Officer
- Kaitlyn Arsenault
- Chief Development Officer
- Tu Diep
- Director
- Deborah Charych
- Independent Director
- Margaret Dalesandro
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $21.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 928.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.54 |
EPS | $-0.02 |
Book Value | $0.01 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
